GT Biopharma, Inc.
Euronext ParisTotal Valuation
GT Biopharma, Inc. carries a market capitalization of 626.73M, placing it among publicly traded companies globally. Its enterprise value stands at -8.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 626.73M |
| Enterprise Value | -8.92M |
Share Statistics
GT Biopharma, Inc. currently has 31.82M shares outstanding.
| Shares Outstanding | 31.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
GT Biopharma, Inc. maintains a current ratio of 4.14, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.14 |
| Quick Ratio | 3.69 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -211.71 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -754.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 3.80 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
GT Biopharma, Inc.'s stock has gained approximately 2900% over the past 52 weeks. The 50-day moving average sits at 280.50, while the 200-day moving average is 280.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2900% |
| 50-Day Moving Average | 280.50 |
| 200-Day Moving Average | 280.50 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.34M, while operating income came in at -13.34M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.34M |
| Pretax Income | -47.73M |
| Net Income | -47.73M |
| EBITDA | -13.34M |
| EBIT | -13.34M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at -726.80M, with working capital of 7.58M providing operational flexibility.
| Cash & Cash Equivalents | 8.92M |
| Total Debt | N/A |
| Net Debt | -8.92M |
| Equity (Book Value) | -726.80M |
| Book Value Per Share | N/A |
| Working Capital | 7.58M |
Cash Flow
GT Biopharma, Inc. produced -13.18M in operating cash flow over the past twelve months.
| Operating Cash Flow | -13.18M |
| Capital Expenditures | N/A |
| Free Cash Flow | -13.18M |
| FCF Per Share | N/A |
Dividends & Yields
The company's payout ratio of 0.58 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 0.58 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Stock Splits
GT Biopharma, Inc.'s most recent stock split took place on February 11, 2021 with a 17:1 split ratio.
| Last Split Date | 2/11/2021 |
| Split Ratio | 17:1 |
Scores
GT Biopharma, Inc. posts an Altman Z-Score of -105.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -105.29 |